Martinistrasse 52
Hamburg, D - 20246
Germany
University of Hamburg - University Medical Center Hamburg-Eppendorf
melanoma, targeted therapy, BRAF and MEK inhibitors, Anticoagulation, Direct oral anticoagulants (DOACs), Factor Xa inhibitors, Progression-free survival (PFS), Overall survival (OS), Platelet aggregation inhibition, Venous thromboembolism (VTE), Immunothrombosis
melanoma, immune-checkpoint inhibitors, neutrophils, S100A8/A9, Biomarker
Programmed cell death ligand 1, cemiplimab, D-dimer, cutaneous squamous cell carcinoma, disease control